Page last updated: 2024-11-13
nothofagin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nothofagin: a dihydrochalcone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 21722188 |
| CHEMBL ID | 4082869 |
| MeSH ID | M0521220 |
Synonyms (17)
| Synonym |
|---|
| nothofagin |
| 11023-94-2 |
| AKOS027446309 |
| 3'-c-glucosylphloretin |
| 3-(4-hydroxyphenyl)-1-[2,4,6-trihydroxy-3-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]propan-1-one |
| 1-[3-[(2s,3r,4r,5s,6r)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-2,4,6-tris(oxidanyl)phenyl]-3-(4-hydroxyphenyl)propan-1-one |
| e7f , |
| HY-113919 |
| bdbm50235138 |
| CS-0064186 |
| CHEMBL4082869 , |
| AT36573 |
| nsc-791582 |
| nsc791582 |
| DTXSID401027257 |
| (1s)-1,5-anhydro-1-{2,4,6-trihydroxy-3-[3-(4-hydroxyphenyl)propanoyl]phenyl}-d-glucitol |
| FS-8058 |
Research Excerpts
Overview
Nothofagin is a mono-C-glycoside of 4,2',4',6'-tetrahydroxy-dihydrochalcone. It is commonly found in Aspalathus linearis, Nothofagus fusca, and Leandra dasytricha.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Nothofagin is a natural 3'-C-β-D-glucoside of the polyphenol phloretin that is mainly found in Aspalathus linearis, Nothofagus fusca, and Leandra dasytricha. " | ( Nitric oxide and Ca Cechinel-Filho, V; da Silva, CHF; de Almeida, CLB; de Souza, P; Gasparotto Junior, A; Lourenço, ELB; Marques, AAM, 2020) | 2 |
| "Nothofagin is a mono-C-glycoside of 4,2',4',6'-tetrahydroxy-dihydrochalcone that is commonly found in Aspalathus linearis, Nothofagus fusca, and Leandra dasytricha. " | ( Nitric oxide/cGMP signaling pathway and potassium channels contribute to hypotensive effects of nothofagin. Cechinel-Filho, V; da Silva, CH; de Almeida, CL; de Souza, P; Gasparotto, A; Lourenço, EL; Palozi, RA, 2020) | 2.22 |
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Nothofagin has been shown to ameliorate various inflammatory responses such as the septic response and vascular inflammation." | ( Nothofagin suppresses mast cell-mediated allergic inflammation. Choi, YA; Kang, BC; Khang, D; Kim, MJ; Kim, SH; Kwon, TK; Lee, S; Park, PH; Shin, TY, 2019) | 2.68 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Nothofagin treatment prevented histamine and β-hexosaminidase release by reducing the influx of calcium into the cytosol in a concentration-dependent manner." | ( Nothofagin suppresses mast cell-mediated allergic inflammation. Choi, YA; Kang, BC; Khang, D; Kim, MJ; Kim, SH; Kwon, TK; Lee, S; Park, PH; Shin, TY, 2019) | 2.68 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Pathways (1)
| Pathway | Proteins | Compounds |
|---|---|---|
| flavonoid di-C-glucosylation | 0 | 29 |
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | IC50 (µMol) | 19.0000 | 0.0607 | 1.6105 | 8.4440 | AID1436776 |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | IC50 (µMol) | 0.0119 | 0.0005 | 0.1653 | 4.1000 | AID1436777 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (18)
Molecular Functions (12)
Ceullar Components (9)
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1436780 | Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake at 100 uM pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence as | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| AID1436777 | Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| AID1436778 | Selectivity ratio of IC50 for human SGLT1 to IC50 for human SGLT2 | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| AID1436776 | Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| AID1436774 | Cytotoxicity in HEK293 cells assessed as cell viability at 100 uM measured after 20 to 24 hrs by Cell-Titer Blue fluorescence assay | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| AID1436779 | Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake at 100 uM pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence as | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| AID1436783 | Inhibition of GLUT in HEK293 cells assessed as reduction in 2-deoxyglucose uptake at 100 uM pretreated for 10 mins followed by 2-deoxyglucose addition in presence of choline buffer measured after 1 hr by resazurin dye based fluorescence assay | 2017 | Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2 | Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (23)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 18 (78.26) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.49
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.49) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 24 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||